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Background: Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory 
infection (ALRI) in children.  We aimed to describe the clinical-epidemiological pattern and risk 
factors for mortality associated with RSV infection. 
Methods: A prospective, cross-sectional study of ALRI in children admitted to the Children’s 
Hospital among 2000-2017. Viral diagnosis was made by fluorescent antibody techniques or real 
time-PCR. We compared clinical-epidemiological characteristics of RSV infection in non-fatal 
versus fatal cases. Multiple logistic regression was used to identify independent predictors of 
mortality.  
Results: Of a total 15,451 patients with ALRI, 13,033 were tested for respiratory viruses and 
5831 (45%) were positive: RSV 81.3% (4738), influenza 7.6% (440), parainfluenza 6.9% (402) 
and adenovirus 4.3% (251). RSV had a seasonal epidemic pattern coinciding with months of 
lowest average temperature. RSV cases show a case fatality rate of 1.7% (82/4687). Fatal cases 
had a higher proportion of: prematurity (p<0.01), perinatal respiratory history (p<0.01), 
malnourishment (p<0.01), congenital heart disease (p<0.01), chronic neurological disease 
(p<0.01) and pneumonia at clinical presentation (p=0.014). No significant difference between 
genders was observed. Most deaths occurred among children who had complications: respiratory 
distress (80.5%), nosocomial infections (45.7%), sepsis (31.7%) and atelectasis (13.4%). 
Independent predictors of RSV mortality were: moderate to severe malnourishment, OR 3.69 
(95% CI 1.98-6.87) p< 0.0001, chronic neurological disease, OR 4.14 (95% CI 2.12-8.08) p< 
0.0001, congenital heart disease, OR 4.18 (95% CI 2.39-7.32) p< 0.0001 and the age less than 6 
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Conclusion: RSV showed an epidemic pattern affecting mostly young children. 
Malnourishment, chronic neurological disease, congenital heart disease and the age less than 6 
months were the independent risk factors for RSV mortality. 











Acute lower respiratory infection (ALRI) is the most common reason for outpatient visits, school 




In Argentina, it is an important cause of 
mortality as well as hospital admissions during the winter months in all age groups, particularly 
in children younger than 5 and adults older than 65 years of age. Most of these infections are 
viral in origin generating significant morbidity and mortality in individuals with risk factors 
3
. 
Respiratory syncytial virus (RSV) is the main cause of bronchiolitis and pneumonia in infants 
and young children worldwide 
4
. Primary infection usually occurs in young children 6 weeks to 2 
years of age 
2,5-9
, and is a leading cause of death in infants less than 6 months.  Mortality rates are 




RSV is spread through direct or indirect contact with nasal and oral secretions of infected 
individuals. Children are primarily responsible for transmission because they have higher viral 
loads than adults 
11
. Reinfections can occur in any stage of life and are usually mild or 
asymptomatic in adults, but can cause severe disease in the elderly 
12
. RSV is also an important 
pathogen in other risk groups such as preterm infants and children with bronchopulmonary 
dysplasia or hemodynamically unstable congenital heart disease 
13
. Worldwide, this virus is 
responsible for 30 million episodes of ALRI and for more than 50,000 deaths per year in children 
younger than 5 years 
14
. A recent publication on global RSV mortality, which included data from 
our hospital, estimated that the virus causes one third of all deaths in children less than one year 
of age 
15
. In Argentina, based on information provided by the National Laboratory-based 
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collected in 2017 between epidemiologic weeks 1 and 44, RSV was the main pathogen found in 
61.4% (n=18,738) of samples, followed by influenza viruses (IF) 20.8% (n=6349)
 16
.  
Given the global burden of RSV disease in children, the aim of this study was to describe the 
clinical and epidemiologic characteristics of RSV-ALRI and estimate case fatality risk factors in 
patients admitted to our hospital.  
Methods 
We conducted a prospective, cross-sectional study. Patients with ALRI acquired in the 
community admitted to the Ricardo Gutierrez Children’s Hospital, Buenos Aires, between 2000 
and 2017 were identified through an active surveillance program.  
Population 
All children less than 18 years of age hospitalized for ALRI acquired in the community, namely 





Patients admitted for other causes who developed ALRI during hospitalization. 
Data collection 
Data was collected using a specific case-report form and included: date of admission, 
demographics (age, sex, city of residence), clinical presentation (bronchiolitis, pneumonia), 
previous hospitalizations for respiratory diseases, readmission within the same episode, co-
morbidities, history of close contact with individuals presenting acute respiratory symptoms of 
probable viral origin (runny nose, cough, and/or fever), perinatal respiratory disorders, 
complications during hospitalization, treatment, length of stay and outcome (discharged home, 
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disease, moderate to severe malnourishment, congenital heart disease, genetic or neurologic 
diseases and immunodeficiency.  
Chronic or recurrent respiratory disease, were also reported, namely, recurrent obstructive 
bronchitis or asthma (two or more episodes of bronchial-obstruction), gastroesophageal reflux 
disease, cystic fibrosis, bronchopulmonary dysplasia, recurrent laryngitis and pneumonia; as 
were in-hospital complications such as nosocomial infections, sepsis, persistent atelectasis, 
pneumothorax, pleural effusion, pulmonary bullae, lung abscesses, ear infections, diarrhea, 
seizures, and meningitis.  
Nosocomial infection was defined as exacerbation of respiratory symptoms not present at 
admission (even if incubation was a possibility), diagnosed in patients hospitalized for ≥48 
hours, presenting fever, increased oxygen requirement or changes in radiologic pattern. 
Diagnostic methods 
World Health Organization guidelines were used for clinical and radiologic diagnosis of 
bronchiolitis and pneumonia 
17
. Viral diagnosis was performed in all cases by indirect 
fluorescent antibody (IFA) testing on nasopharyngeal specimens. After real-time polymerase 
chain reaction (RT-PCR) assay became available in 2009, it has been used together with IFA test 
to detect RSV, IF A and B, parainfluenza (PIF) and adenovirus (AV). Commercially available 
kits were used in all cases. 
Statistical analysis 
Categorical variables were analyzed using the χ2 test with Yates correction. We used the 
Wilcoxon test for median age comparison.  Odds ratio (OR) with 95% confidence interval (CI) 
was used for association analysis; a bivariate analysis was performed initially to identify 
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establish independent predictors of case fatality. P values < 0.05 were considered statistically 
significant. STATA / SE version 13 was used for the analysis. 
Multivariate analysis 
A logistic regression model was constructed to identify the predictors of mortality by RSV. The 
variables with significant association with death in the crude analysis and / or those considered 
clinically relevant, were added one at a time in the multivariate model and only those 
significantly associated with the outcome in the multivariable context (Wald test) were retained 
in the final model. We checked the changes on the coefficients in order to find confounding 
variables.  
Calibration and discrimination 
The calibration and discrimination of the model were evaluated with the Hosmer-Lemeshow 
goodness-of-fit test and the area under the ROC curve. 
Seasonality 




Privacy rights of patients were observed in all cases in accordance with the World Medical 
Association Declaration of Helsinki International Code of Ethics for experiments involving 
humans. Patient’s informed consent is not applicable in this study because data were obtained 
from a routine epidemiologic surveillance activity included in the framework of Argentinean 
Law 15465/60. The study was approved by the Ethics and Research Committees of the Ricardo 
Gutierrez Children’s Hospital. This study will not affect human rights, nor will it cause damage 










A total of 15,451 patients were admitted for ALRI acquired in the community over a period of 18 
years, from them 13,033 (84%) children were tested for respiratory viruses and 5,831 (45%) had 
positive results (see Figure, Supplemental Digital Content 1, http://links.lww.com/INF/D397).  
RSV predominated throughout the entire study period (4738, 81.3%), followed by IF (440, 
7.6%), PIF (402, 6.9%) and AV (251, 4.3%).  
RSV had a seasonal epidemic pattern (viral activity onset and offset 18 and 33 epidemiologic 
weeks respectively) coinciding with months of lowest median temperature and highest relative 
humidity (May-July). (Figure 1) 
In our study population there was a slight predominance of boys (56.5%), and the median age 
was 7 months (IQR 2-12); almost two thirds were infants less than 12 months and 42% less than 
6 months of age.  
The distribution of the different clinical and epidemiologic characteristics of patients with RSV 
disease and their relationship with the outcome (death) is expressed in Table 1, comparing non-
fatal and fatal cases.  
RSV case fatality rate was 1.7% (82/4687).  
The annual mortality rate distribution was not stable over the study period with the highest 
mortality in the year 2002. (Figure 2) 
In fatal cases, the most frequent complications were respiratory distress (80.5%), nosocomial 
infections (45.7%), sepsis (31.7%) and atelectasis (13.4%) (Table 2). 
Independent predictors of RSV mortality were: moderate to severe malnourishment, chronic 
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The final model achieved good calibration (p=0.85) and discrimination with an area under the 
ROC curve of 0.712.  
Discussion  
In this study, we evaluated the characteristics and outcome of patients with RSV-ALRI based on 
active surveillance and systematic data collection over a period of 18 years. Active surveillance 
of ALRI is crucial for rapid detection of increase in number of cases, identification of high risk 
groups and to determine the frequency, distribution and characteristics of disease-causing agents 
19,20
.  
RSV was the most frequent pathogen found in positive samples from the patients included in our 
center (81.3%) and that incidence was highest in infants less than one year of age (74% of cases). 
These results are similar to those of other epidemiologic studies carried out in the region 
21-23
.  
RSV circulation showed a seasonal epidemic pattern as seen in temperate climate regions. Onset 
and offset of viral activity were registered during epidemiologic weeks 18 and 33 respectively, 
coinciding with months of lowest median temperature and highest relative humidity in Argentina 
(May-July) 
23
. Kamigaki et al. found that mean temperature and specific humidity were also 
positively associated with influenza and RSV at Philippine sites
24
. In addition, Meerhoff et al., 
reported that the combination of both (temperature and humidity) contribute more to RSV 
activity than each factor independently 
25
. Furthermore, Walton et al. showed that real time 
weather forecasts have the potential to predict RSV outbreaks 
26
. Although we found a similar 
epidemic seasonal pattern, a proper time-series analysis is needed to draw robust conclusions as 
the mentioned authors  
Around the world, 1-3% of healthy children are hospitalized as result of RSV respiratory 
infections during the first year of life.
2,3,6,27
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children younger than one year of age, patients with underlying conditions such as prematurity, 
congenital heart disease, malnutrition and chronic neurologic disease showed higher rates of 
mortality 
28-29
. In a meta-analysis on incidence and mortality of RSV infections in children, Stein 
et al. concluded that the virus was an important cause of hospitalization and mortality, and that 
gestational age was a critical determinant of disease severity in the first year of life 
30
. 
Unfortunately as we have not recorded gestational age data in the whole series we could not 
include this variable in the analysis. 
Although being a boy was found to be a risk factor in some studies
 31
, we did not observe 
significant gender differences in our population. Regarding congenital heart disease (CHD) a 20 
years systematic review was undertaken across studies reporting data for hospital 
visits/admissions for RSV infection among children with CHD, concluding that young children 
with CHD have a significant risk for RSV mortality 
32
. This risk is specially for severe disease 
and hospitalization and, in some instances, may require admission to the intensive care unit 
(ICU), supplemental oxygen therapy and prolonged mechanical ventilation
33,34
. 
In a study based on national data sets, Byington et al. also found children with complex chronic 
conditions accounted for most RSV associated deaths 
35
. Scheltema et al. also found that more 
than half of all children included in the RSV Gold RSV associated study had a weight for age of 
less than −2 SDs
15
.  García et al. describe several factors that independently correlated with the 
severity of illness as trisomy 21, lower weights on admission, neuromuscular disorders 
28
.  
Death from RSV infection was more common in patients requiring mechanical ventilation, 
longer hospital length of stay, presenting sepsis and atelectasis, in line with other regional 
studies
36,37
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such as sepsis or respiratory failure. Moreover many children have more than one complication 
during hospitalization.  
Case fatality rate was 1.7% (82/4687) similar to values reported by Nair et al. who found rates of 
0.3 and 2.1% in children under 5 years and 0.7 and 2.1% in infants (<1 year of age) for 
industrialized and developing countries, respectively 
38
.  
One of the strengths of this study lies in its methodologic design, a prospective active 
surveillance based on robust epidemiologic data, a sample large enough that allows statistical 
robust conclusions and individual data of each patient. The model showed good calibration and 
discriminative capacity in the studied population.  
In addition indirect immunofluorescence test is recommended for rapid detection and diagnosis 
of respiratory viruses. This method is widely used because it is a simple, quick, low-cost test 
with high specificity and sensitivity detecting viruses that usually cause ALRI, namely RSV, IF, 
PIF and AV 
38-41
.  
As a limitation, this study was conducted in a single tertiary hospital, so the complexity of our 
patients makes it difficult to extrapolate results to the general population. The high proportion of 
comorbidities in our patients perhaps overestimates the more severe RSV symptoms when we 
analyzed complications. Moreover, hospital case-fatality ratios cannot be translated to 
population-based mortality. 
Around 60 different strategies to prevent RSV infection are being developed involving candidate 
vaccines and human monoclonal antibodies, of which 16 are currently undergoing phase I-III 
studies 
42






Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
12 
 
crucial to assess the effectiveness and impact of new RSV vaccines, as well as for establishing 
age-specific immunization strategies and harmonizing health care policies 
43
.  
In conclusion, multiple independent characteristics have been identified that significantly 
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   Age  
   n (%) 
Median (months); IQR 7; 3-12 5; 2-11 7; 3-12 0.1 
 < 6 months 2022 (42.7) 1961 (42.6) 42 (51.2) 0.15 
 < 12 months 3505 (74) 3379 (73.5) 63 (76.8) 0.58 
Sex (boys) n (%) 2679 (56.5) 2578 (56.6) 41 (50) 0.27 
Prematurity n (%) 655 (13.85) 629 (13.7) 20 (24.4) 0.008 
Neonatal respiratory history n (%) 527 (11.15) 500 (10.9) 21 (25.6) <0.01 
Immunosuppression n (%) 87 (1.84) 83 (1.8) 2 (2.4) 0.99 
Malnourishment n (%) 218 (4.62) 197 (4.3) 17 (20.7) <0.01 
Previous hospitalizations for 
respiratory causes n (%) 
1246 (26.4) 1193 (26) 36 (43.9) <0.01 
Re-admission for same episode        n 
(%) 
153 (3.24) 141 (3.1) 7 (8.5) 0.012 
Pneumonia as clinical presentation   n 
(%) 
1832 (38.7) 1772 (38.5) 43 (52.4) 0.014 
Comorbidities 
n (%) 




1339 (28.27) 1306 (28.4) 21 (25.6) 0.67 
Congenital heart 
disease 
282 (5.85) 263 (5.7) 19 (23.2) <0.01 
Chronic neurologic 
disease 
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Total n (%) 5121* 981 (21.3) 77 (93.9) <0.01 
Respiratory distress 380 (8) 312 (6.8) 66 (80.5) <0.01 
Atelectasia 179 (3.8) 168 (3.6) 11 (13.4) <0.01 
Sepsis 149 (3.18) 120 (2.6) 26 (31.7) <0.01 
Nosocomial Infection 288 (6.3) 251 (5.6) 37 (45.7) <0.01 
Length of hospital stay   
median (days);  IQR 
7 (5-10) 7 (5-10) 17 (8-31) <0.01 
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Table 3: Results of the final model of Multiple Logistic Regression: independent predictors 
for RSV mortality 
Variables OR 95% CI p 
Malnourishment 3.69 1.98-6.87 < 0.0001 
Chronic neurologic disease 4.14 2.12-8.08 < 0.0001 
Congenital heart disease 4.18 2.39-7.32 < 0.0001 
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Fatal cases (n) 6 7 13 11 10 5 1 4 5 0 0 5 5 2 4 2 1 1
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